Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE vs HEMICLOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions. Potassium repletion corrects hypokalemia and associated disorders.
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Treatment or prevention of hypokalemia,Digitalis intoxication,Familial periodic paralysis (hypokalemic form),Diuretic-induced hypokalemia
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
Oral: 40-100 m Eq/day in divided doses; IV: up to 10-20 m Eq/hour via central line, max 40 m Eq/hour with continuous monitoring; not to exceed 200 m Eq/day.
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
Not applicable; potassium is an electrolyte regulated by homeostasis, not classic elimination half-life. Under normal renal function, serum half-life of administered potassium is approximately 2-4 hours due to rapid cellular uptake and renal excretion.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Potassium is not metabolized; it is excreted primarily by the kidneys. Approximately 90% is excreted in the urine, with the remainder in feces and sweat. Renal excretion is influenced by aldosterone.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Primarily renal (90%) as potassium ion; minimal fecal (<10%) and sweat.
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Minimal; <2% bound to plasma proteins.
70–80% (primarily to albumin).
0.5-0.7 L/kg; distributes primarily to intracellular compartment (98% of total body potassium is intracellular).
0.3–0.5 L/kg (indicates moderate tissue distribution).
Oral: 90-100% (well absorbed from gastrointestinal tract, subject to first-pass uptake by liver; bioavailability is near complete).
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
e GFR >50: no adjustment; e GFR 10-50: reduce dose by 25-50%; e GFR <10: avoid or use with extreme caution, starting at 50% of usual dose.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
No specific adjustment required for Child-Pugh A, B, or C; monitor potassium levels closely due to risk of hyperkalemia.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Oral: 1-3 m Eq/kg/day in divided doses; IV: 0.25-0.5 m Eq/kg/hour, max 1 m Eq/kg/hour with cardiac monitoring; max daily dose 3 m Eq/kg/day.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Start at low end of adult dosing (e.g., 20 m Eq/day) and titrate slowly; monitor renal function and potassium levels frequently due to decreased renal reserve.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Potassium chloride injection concentrate must be diluted before use. Undiluted administration can result in fatal cardiac arrest. Also, potassium supplements should not be used in patients with hyperkalemia or conditions that predispose to hyperkalemia.
No FDA black box warning is present for HEMICLOR.
Cardiac arrest if administered too rapidly or in concentrated form,Hyperkalemia risk especially in renal impairment, diabetes, or concurrent use of ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics,Gastrointestinal irritation with oral solid formulations; use with caution in patients with esophageal compression or delayed GI transit,Monitor serum potassium and ECG during parenteral therapy,Avoid potassium chloride in patients with severe burns, crush injuries, or other conditions that lead to rapid cellular breakdown
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Hyperkalemia (serum potassium >5.5 m Eq/L),Severe renal impairment with oliguria or anuria,Uncontrolled Addison's disease,Acute dehydration,Concurrent use with potassium-sparing diuretics (e.g., spironolactone, eplerenone, amiloride, triamterene),Solid oral forms in patients with conditions that delay GI transit or esophageal compression
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Avoid potassium-rich foods in excess (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados, dried fruits, salt substitutes) unless instructed by your doctor. Do not take with alcohol or excessive coffee/tea, which may affect electrolyte balance.
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
Potassium chloride is not teratogenic. There is no evidence of fetal harm from oral or intravenous administration at therapeutic doses, provided maternal potassium levels are maintained within normal range. No trimester-specific risks identified; however, maternal hypokalemia or hyperkalemia can adversely affect fetal outcomes (e.g., arrhythmias, growth restriction).
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Potassium is a normal constituent of breast milk. Potassium chloride supplementation at recommended doses is considered compatible with breastfeeding. Maternal milk-to-plasma (M/P) ratio is approximately 0.1-0.3, indicating low transfer. No adverse effects in nursing infants reported.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
Dosing adjustments not required specifically due to pregnancy. However, increased plasma volume in pregnancy may dilute serum potassium; dose should be guided by serum potassium levels and clinical need. No evidence of altered pharmacokinetics requiring dose change.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
Potassium chloride is the preferred salt for replacement due to high chloride content which corrects metabolic alkalosis. Always administer IV potassium at a rate not exceeding 10-20 m Eq/hour peripherally, and 10-40 m Eq/hour centrally with continuous ECG monitoring. Never give IV potassium undiluted; maximum concentration for peripheral IV is 10 m Eq/100 m L. In severe hypokalemia (K+ < 2.5 m Eq/L), consider cardiac monitoring and admission. Oral potassium should be taken with food to minimize gastric irritation. Caution in renal impairment and with potassium-sparing diuretics or ACE inhibitors.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
Take potassium chloride with food or after a meal to prevent stomach upset.,Do not crush or chew extended-release tablets; swallow whole with a full glass of water.,Use the oral solution only if it is clear; do not mix with other drinks without asking your doctor.,Do not use salt substitutes (which contain potassium) while taking potassium supplements unless directed.,Report symptoms of high potassium levels: muscle weakness, irregular heartbeat, tingling in hands/feet, or confusion.,Keep all appointments for blood tests to monitor your potassium levels.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE vs HEMICLOR, answered by our medical review team.
POTASSIUM CHLORIDE is a Electrolyte Supplement that works by Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions. Potassium repletion corrects hypokalemia and associated disorders.. HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE and HEMICLOR depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE is: Oral: 40-100 m Eq/day in divided doses; IV: up to 10-20 m Eq/hour via central line, max 40 m Eq/hour with continuous monitoring; not to exceed 200 m Eq/day.. The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE and HEMICLOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE is classified as Category C. Potassium chloride is not teratogenic. There is no evidence of fetal harm from oral or intravenous administration at therapeutic doses, provided maternal potassium levels are maint. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.